Skip to content

Study on Adherence to a Mediterranean Diet in a Population of Patients With Type 2 Diabetes

Study on Adherence to a Mediterranean Diet in a Population of Patients With Type 2 Diabetes Diet-Med

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05292833
Acronym
DIET-MED
Enrollment
60
Registered
2022-03-23
Start date
2023-07-06
Completion date
2024-05-26
Last updated
2026-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Type 2 diabetes, Mediterranean Diet

Brief summary

In randomized clinical studies, the mediterranean diet has demonstrated beneficial effects on glucose and lipids levels, on body composition, on waist to hip ratio, especially in patients with type 2 diabetes. Consequently, the meditteranean diet is now recommended by experts in cardiology, nutrition and diabetology. However, many of these publications have been generated in populations living around the Mediterranean Basin. Thus, it is not sure that this diet can be used by people living outside this geographic area. We aimed to study the capacity of consecutive patients admitted in diabetology to follow the mediterranean diet recommandations during 12 months. The adherence will be studied in the real life in order to identify all limitations to follow this diet. Therefore, this study may help to find solutions to reinforce adherence to this diet.

Detailed description

Patients older than 18 years of age and consequently admitted in the Dpt of Diabetology in the Pitié-Salpêtrière and the Georges Pompidou Euopean Hospitals will be enroled in this study. After a survey of eating habits, the 14 items of the mediterranean diet (accordingly to Schröder H et al., J Nutr 2011) will be explained. Adherence to the diet is defined by the achievement of more than 9 items from the original list of 14 items. Adhesion to the diet will be studied à 3 and 12 months by questionnaires and the analysis of olive oil consumption (urine levels of hydroxytyrosol and alpha linoleic acid levels in bloood). Consequences of adhesion to the diet on body weight, body composition, glucose and lipids levels, HbA1c and liver enzymes in blood will be collected at 3 and 12 months. At the end of the study, patients will complete a semi-quantitative questionnaire with a sociologist in order to identify main limitations to achieve items of the diet.

Interventions

None listed

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient over 18 years old. * Patient with type 2 diabetes regardless of the hypoglycaemic treatments used and their HbA1c level. * Patient referred to the Diabetology day hospital of the CHU Pitié-Salpêtrière and Nutrition of the HEGP for assessment of diabetes and/or for obesity assessment and dietary education as part of routine care. * Patient accepting the constraints of the protocol after explanation of it and not opposing to participate in it. * Patient benefiting from or entitled to health insurance coverage outside of the AME.

Exclusion criteria

* Patient with current or recent infections (\<10 days). * Patient with unstable neoplastic (with the exception of carcinoma in situ of the cervix or cutaneous epithelioma), hematological, psychiatric (with the exception of eating disorders (ED)). * Pregnant or breastfeeding patient. * Person under legal protection.

Design outcomes

Primary

MeasureTime frameDescription
The percentage of patients adhering to the Mediterranean Diet12 monthsThis pourcentage is defined as an adherence score ≥ 9 in response to the 14-item questionnaire adapted from Schröder H et al., J Nutr 2011

Secondary

MeasureTime frameDescription
Association between adherence and variations in the values of urinary hydroxytyrosolat inclusion, at 3 months and at 12 monthsQuestionnaire of the 14 objectives Weekly food frequency questionnaire (INPES and INVS)
Association between adherence and variations in the values of blood alpha linolenic acidat inclusion, at 3 months and at 12 monthsQuestionnaire of the 14 objectives Weekly food frequency questionnaire (INPES and INVS
Association between variations in urinary hydroxytyrosol values compared to inclusion and the declaration of an increase in olive oil consumption during follow-up.at 3 months and 12 monthsIn grams per day
Association between variations in blood alpha linolenic acid values compared to inclusion and the declaration of increased consumption of walnuts during follow-up.at 3 and 12 monthsIn grams per day
Association between variations in blood alpha linolenic acid values compared to inclusion and the declaration of increased consumption of hazelnuts during follow-up.at 3 and 12 monthsIn grams per day
Association between variations in blood alpha linolenic acid values compared to inclusion and the declaration of increased consumption of almonds during follow-up.at 3 and 12 monthsIn grams per day
To study whether adherence at baseline predicts adherence to Mediterranean Diet.at 3 months and 12 monthsQuestionnaire of the 14 objectives Weekly food frequency questionnaire (INPES and INVS)
Study whether adherence to the Mediterranean Diet modifies the frequency of food consumptionduring follow-up (12 months)Using questionnaires from the 2011-2012 Abena study (INPES and INVS)
Describe the difficulties/barriers to the initiation of the Mediterranean Dietat Day 15, at Day 60 and at Day 180By repeated telephone contacts by a dietician. During these telephone contacts, the dietician will take up the 14-item grid and evaluate with the patient the difficulties or aspects already implemented. The evolution of the 14-item grid will make it possible to analyze any difficulties encountered during contacts in order to report the progress made or the regression in the number of items made over time.

Countries

France

Contacts

STUDY_DIRECTORCéline BENOIT, Mrs

APHP

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026